港股异动 | 沛嘉医疗-B(09996)盘中涨超6% GeminiOne TEER系统已成功完成美国EFS中的首例患者植入

智通财经04-10

智通财经APP获悉，沛嘉医疗-B(09996)盘中涨超6%，截至发稿，涨3.83%，报6.5港元，成交额352.34万港元。消息面上，4月9日，沛嘉医疗-B发布公告，GeminiOne®经导管缘对缘修复(TEER)系统于美国食品药品监督管理局(FDA)早期可行性研究(EFS)中的首例患者植入已成功完成。该手术由HCA Healthcare旗下Los Robles Regional Medical ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2626157150?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-10 10:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626157150","market":"sh","top_or_hot":-1,"title":"港股异动 | 沛嘉医疗-B(09996)盘中涨超6% GeminiOne TEER系统已成功完成美国EFS中的首例患者植入","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，沛嘉医疗-B(09996)盘中涨超6%，截至发稿，涨3.83%，报6.5港元，成交额352.34万港元。消息面上，4月9日，沛嘉医疗-B发布公告，GeminiOne®经导管缘对缘修复(TEER)系统于美国食品药品监督管理局(FDA)早期可行性研究(EFS)中的首例患者植入已成功完成。该手术由HCA Healthcare旗下Los Robles Regional Medical ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1426922.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 沛嘉医疗-B(09996)盘中涨超6% GeminiOne TEER系统已成功完成美国EFS中的首例患者植入</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 沛嘉医疗-B(09996)盘中涨超6% GeminiOne TEER系统已成功完成美国EFS中的首例患者植入\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-10 10:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1426922.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，沛嘉医疗-B(09996)盘中涨超6%，截至发稿，涨3.83%，报6.5港元，成交额352.34万港元。消息面上，4月9日，沛嘉医疗-B发布公告，GeminiOne®经导管缘对缘修复(TEER)系统于美国食品药品监督管理局(FDA)早期可行性研究(EFS)中的首例患者植入已成功完成。该手术由HCA Healthcare旗下Los Robles Regional Medical ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1426922.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09996","symbol_name":"沛嘉医疗-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1426922.html","article_id":"2626157150","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626157150","pubTimestamp":1775788516,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，沛嘉医疗-B盘中涨超6%，截至发稿，涨3.83%，报6.5港元，成交额352.34万港元。消息面上，4月9日，沛嘉医疗-B发布公告，GeminiOne经导管缘对缘修复系统于美国食品药品监督管理局早期可行性研究中的首例患者植入已成功完成。公司第三代长效干瓣TaurusNXT已于2025年12月获NMPA受理，GeminiOne TEER已在中国递交注册申请并同步推进欧盟MDR CE申请，HighLife TMVR注册临床持续推进。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159891":"医疗","09996":"沛嘉医疗-B","BK1100":"医疗保健设备","BK1574":"生物医药B类股","BK4585":"ETF&股票定投概念","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","BK1583":"高瓴概念"},"translate_title":"Hong Kong stock changes | Peijia Medical-B (09996) rose more than 6% intraday. GeminiOne TEER system has successfully completed the first patient implantation in U.S. EFS","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159891":1.5,"09996":1.5,"VXUS":1.5},"content_text":"智通财经APP获悉，沛嘉医疗-B(09996)盘中涨超6%，截至发稿，涨3.83%，报6.5港元，成交额352.34万港元。消息面上，4月9日，沛嘉医疗-B发布公告，GeminiOne®经导管缘对缘修复(TEER)系统于美国食品药品监督管理局(FDA)早期可行性研究(EFS)中的首例患者植入已成功完成。该手术由HCA Healthcare旗下Los Robles Regional Medical Center结构性心脏病介入与临床研究主任、加州大学洛杉矶分校大卫 • 格芬医学院临床医学教授Saibal Kar教授主刀完成。中金此前研报指出，沛嘉医疗-B 2025年瓣膜业务收入2.90亿元，同比+11.6%，首次实现瓣膜业务正向贡献。公司第三代长效干瓣TaurusNXT已于2025年12月获NMPA受理，GeminiOne TEER已在中国递交注册申请并同步推进欧盟MDR CE申请，HighLife TMVR注册临床持续推进。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626157150","isCrawlerRequest":true}